Martin Erixon joins Hamlet Pharma as new CEO

By April 19, 2022 October 23rd, 2022 No Comments

Hamlet Pharma enters a new business development phase involving multiple cancer indications and markets. Based on the successful outcomes of our clinical trial program, we are progressing towards Phase III trials and are expanding our product portfolio. 

Martin Erixon has extensive experience from the Medical/Pharmaceutical industry as well as from the Food Processing industry. Based on a Ph.D. in Chemistry from the University of Lund and a Master of Science, Martin Erixon has developed a successful career in large corporations such as Gambro (Baxter) and Tetra Pak, one of the largest food packaging companies in the world. He combines strong leadership with excellent communication skills and has successfully built relationships with different stakeholders both in Gambro (Baxter) and Tetra Pak. Martin Erixon is a highly motivated team player and negotiator, who strives to find the best solutions in business relationships. In his capacity as advisor to Hamlet Pharma, Martin Erixon has facilitated the discussions with external partners in recent years.

The current CEO Mats Persson will stay in the company and continue to support the clinical trial program. Mats Persson has made invaluable contributions to the the development of the company and of Alpha1H into a strong drug candidate for bladder cancer. We are particularly grateful to him for his leadership during the past five years.  

“We are delighted to announce that Martin Erixon is joining Hamlet Pharma”, says Catharina Svanborg, Chairman of Hamlet Pharma AB.  We are also grateful that Mats Persson continues to support the company with his extensive experience.

For more information, please contact

 Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49

 Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57 

About HAMLET Pharma

HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in human milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects against bladder cancer in animal models. In an ongoing clinical trial with Alpha1H in patients with bladder cancer, potent tumor responses have been demonstrated compared to patients who received placebo. The results from the ongoing clinical study show no drug-related side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Bladder cancer is a common and costly form of cancer that is difficult to treat and has been declared an unmet medical need. HAMLET Pharma is further expanding its activities into other cancer indications. In addition, Hamlet Pharma has initiated the drug development phase of BAMLET; a molecular complex of bovine α-lactalbumin and oleic acid. Data from animal models show that local BAMLET treatment may be effective against cancers such as colon cancer.

Hamlet Pharma

Author Hamlet Pharma

More posts by Hamlet Pharma

Hamlet Pharma AB

Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00